Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study)

Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study)

Introduction The PRaG regimen, which consists of hypofractionated radiotherapy combined with a programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitor and granulocyte-macrophage colony stimulating factor (GM-CSF), has been demonstrated to have a survival benefit in patients wit...

Full description

Bibliographic Details
Main Authors: Yong Peng, Hong Zhang, Junjun Zhang, Liyuan Zhang, Pengfei Xing, Yuehong Kong, Rongzheng Chen, Meiling Xu, Guangqiang Chen, Zhihui Hong, Xiaoxiao Dai, Yifu Ma, Xiangrong Zhao, Chenyang Zhang
Format: Article
Language:English
Published: BMJ Publishing Group 2024-03-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/3/e075642.full

Internet

https://bmjopen.bmj.com/content/14/3/e075642.full

Similar Items